Taktile Secures $54M to Enable Risk Experts to Take Control of AI Adoption for Decision Making in Financial Services
27.2.2025 13:00:00 CET | Business Wire | Press release
Taktile – a category-defining decision automation platform – has raised $54 million in a Series B funding round, to continue empowering teams at fintech companies and financial institutions to optimize their risk management strategies across the entire customer lifecycle. The round was led by Balderton Capital, with participation from existing investors Index Ventures, Tiger Global, Y Combinator, Prosus Ventures, Visionaries Club as well as Larry Summers, former US Secretary of the Treasury, bringing Taktile’s total funding to date to $79 million.
In 2024, Taktile quadrupled its customer base and grew over 3.5x in ARR. Its customer base spans 24 markets, encompassing sophisticated fintech companies such as Mercury, Kueski, and Zilch, as well as some of the world's largest financial institutions, including Allianz and Rakuten Bank.
The company has been recognized as a category leader by G2, a leading user review platform, for three consecutive quarters, most recently earning over 12 accolades in its Winter 2025 report. Reflecting its impact once implemented within an organization, Taktile has also gained industry recognition. At the 2024 Banking Tech Awards USA, hosted by FinTech Futures, Taktile won the “Tech of the Future – Decision Making” award.
Taktile’s decision platform is already delivering hundreds of millions of risk decisions every month and the additional funds will be used to accelerate this momentum further as Taktile is equipping business teams with the necessary tools and controls to build transparent AI-powered risk decisioning.
In high-stakes industries, AI adoption must be guided by experts with deep risk domain expertise.
While AI has been broadly adopted for use cases such as chatbots in customer support and real-time personalization in marketing, mainstream automation for high-stakes decisions is just about to break through in 2025. The main difference in applying AI to risk decisions in financial services, such as credit underwriting, account opening, or transaction monitoring, is that errors are extremely costly. Wrong decisions can result in costly loan defaults, fraud losses, preventing good customers from accessing services, or compliance fines by regulators. Only last October TD Bank agreed to pay $3.1 billion to resolve allegations claiming it failed to implement adequate controls to detect and prevent money laundering as regulators across the globe become more concerned with transaction-level controls.
In financial services and other regulated industries, the stakes are high, and every decision matters. Established institutions face intense pressure as AI-driven fintech startups rapidly innovate, challenging their market share and margins. However, many enterprises struggle to adopt AI at scale. The main hurdles? A shortage of highly skilled engineers to develop and maintain AI systems, plus the need for greater precision—since even the most advanced LLMs today can only handle specific aspects of complex problems, rather than providing fully reliable solutions. As Goldman Sachs CEO David Solomon put it: “95% of an S1 filing can be completed by AI in just a few minutes.” However, he continues, “The last 5% now matters because the rest is now a commodity.”
Founded by CEO Maik Taro Wehmeyer, and CPTO Maximilian Eber, Taktile closes this gap by equipping risk teams and their engineering counterparts with a shared platform to build, manage and optimize complex AI-powered workflows and agents that are governed by rules and embedded into business logic. Transforming AI from just an experiment, to something that delivers genuine business value.
Maik Taro Wehmeyer, CEO & Co-founder, Taktile said: “From day one of our journey, we believed that millions of lives could be improved by enabling organizations to make optimal decisions for their customers. By keeping experienced risk experts in control, we make it possible for even the most regulated businesses in financial services to fully adopt AI into high-stakes workflows.”
Rob Moffat, General Partner at Balderton Capital, said: “The best investments for VCs are when your reaction to the company is “of course - why doesn’t this happen already?”. It is crazy that businesses use a plethora of separate tools for different decisions across their business when it is the same customer and data. It is also crazy that a lot of decisioning is coded in-house from scratch. Taktile’s integrated decisioning platform allows businesses to take one consistent view of the customer and easily build, iterate and test complex decision logic. This has won them some of the most sophisticated fintechs as happy clients and is now allowing them to expand into banks and insurers.”
Moving AI adoption in financial services beyond the hype
Over the past 12 months, Taktile has helped its customer Zilch reduce service provider and usage costs by 50% by giving their risk team the tools to build, test, and optimize automated underwriting workflows themselves.
“Taktile’s platform has empowered our teams to take control of our automated underwriting processes, allowing us to build, test, and optimize decisions with unprecedented speed and independence,” said Chanuka Perera, Head of Credit Risk at Zilch. “This shift has not only streamlined our operations but has also resulted in significant cost savings, freeing up resources for further innovation.”
In addition, Taktile has helped Zippi make its decision-making process more efficient by enabling 67% faster policy logic deployment, doubling experimentation across fraud, credit, and portfolio workflows, and ensuring real-time, scalable decision-making without performance bottlenecks. This has allowed Zippi to scale its operations more effectively and process significantly more applications with the same resources. The platform has also reduced Breakout Finance’s underwriting time by 95%, enabling their risk team to handle 3-5x more applications and scale rapidly.
Pieter Viljoen, CDO at Allianz Partners, said: “It was clear that we needed a partner who fully understood the nuances of decisioning in various use cases and industries, the challenges that come with off-the-shelf AI models, and who could provide the required infrastructure to deploy LLMs in mission-critical workflows. We met Taktile just at the right time.”
To explore Taktile’s risk decisioning platform further, please visit our website at www.taktile.com
About Taktile: Taktile empowers risk experts to build, monitor, and optimize automated risk decisions across the entire customer lifecycle—from onboarding and credit underwriting to fraud and compliance transaction monitoring. Taktile’s risk decisioning platform is recognized as category leader in G2’s Winter 2025 Report for Decision Management Platforms and is trusted by leading fintechs, banks and insurers across the globe. The company is headquartered in New York City and has offices in Berlin and London.
About Balderton Capital: Balderton Capital is a multistage venture firm with more than two decades of experience supporting Europe’s best founders from Seed to IPO. We have both early and growth funds and invest across the technology sector, with a proven track record backing AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplace companies. Previous investments include Darktrace (LON: DARK), Depop, Flywire (NASDAQ: FLYW), Kobalt, MySQL, Nutmeg, Peakon, Recorded Future, Talend (NASDAQ: TLND) and THG (LON: THG). Balderton’s current portfolio includes: Aircall, Beauty Pie, Contentful, Dream Games, GoCardless, Lendable, Matillion, Merama, Photoroom, Revolut, Tibber, Wayve, Writer and ZOE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227372584/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom